Building Intelligence Recaps Strong 2025 Growth and Launches New Platform to Power the Next Era of Temporary Access Management

New York City, NY, Jan. 08, 2026 (GLOBE NEWSWIRE) — Building Intelligence, a global provider of temporary access management systems (i.e, visitor, vehicle and vendor management) for commercial properties, today announced a recap of key 2025 milestones and unveiled its new platform architecture for 2026 — including the launch of its first solution built on […]

Final Call: $1M Investment Opportunity for Deep-Tech Startups as Luminate NY Application Window Closes Jan. 12

ROCHESTER, N.Y., Jan. 08, 2026 (GLOBE NEWSWIRE) — Early-stage technology companies have just four days remaining to secure a spot in Cohort 9 of Luminate NY, the world's largest business accelerator for technologies enabled by optics, photonics, and imaging (OPI). With applications closing at 11:59 PM EST on January 12, 2026, founders are invited to

Alliance Entertainment Appoints Jeffrey Smith as Senior Vice President of Sales and Marketing for Alliance Authentic(TM)

(NASDAQ:AENT), PLANTATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Alliance Entertainment Holding Corporation (NASDAQ: AENT), the world's largest distributor of vinyl records and a leading curator of physical entertainment products and collectibles, today announced the appointment of Jeffrey Smith as Senior Vice President of Sales and Marketing for Alliance Authentic(TM), the company's newly launched premium

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

(NASDAQ:ALXO), – First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – – Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H

TON Strategy Company Announces Senior Officer Appointments

(NASDAQ:TONX), LAS VEGAS, Jan. 08, 2026 (GLOBE NEWSWIRE) — TON Strategy Company (Nasdaq: TONX), a digital asset treasury company dedicated to holding Toncoin ($TON), today announced the appointments of Mary L. Marbach as General Counsel and Corporate Secretary and Bill J. Rivard as Chief Accounting Officer, effective January 5, 2026. Ms. Marbach brings more than

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

(NasdaqGM:ARDX), Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 IBSRELA expected to achieve $410-430 million in revenue in 2026 IBSRELA revenue expected to reach $1 billion in 2029 WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) —

Behavioral Labs Inc. (BLINC) and Samsung Partner to Deliver Dynamic Software Solutions

CANTON, Ohio, Jan. 08, 2026 (GLOBE NEWSWIRE) — Behavioral Labs Inc. (BLINC) today announced a new partnership with Samsung Electronics America, Inc. to develop dynamic software solutions that strengthen Samsung Visual eXperience Transformation (VXT), the company's cutting-edge content management ecosystem. The partnership combines Samsung's industry-leading display hardware and VXT solution with BLINC's innovative software capabilities

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

(NASDAQ:ALLO), 1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for Early Q2 2026 Initial Proof-of-Concept for ALLO-329, the Dual CD19/CD70 AlloCAR

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

(NASDAQ:XLO), Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program

KraneShares U.S. Hedged Equity ETF (KSPY) Joins LPL Financial’s No-Transaction-Fee Platform

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — KraneShares, a leading provider of exchange-traded funds (ETFs) delivering access to emerging technologies and innovative global asset classes, today announced that the KraneShares Hedgeye Hedged Equity Index ETF (NYSE: KSPY) has been added to LPL Financial's No-Transaction-Fee (NTF) platform, expanding accessibility for LPL's more than 22,000 financial

Scroll to Top